Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22.

PMID:
31439579
2.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

PMID:
31209337
3.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
4.

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6.

PMID:
30413379
5.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group.

Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013.

6.

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC.

Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26.

7.

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS.

Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10.

PMID:
28335887
8.

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Breast. 2016 Oct;29:153-9. doi: 10.1016/j.breast.2016.07.017. Epub 2016 Aug 5.

PMID:
27498129
9.

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

Jebbink M, van Werkhoven E, Mandjes IA, Wesseling J, Lips EH, Vrancken Peeters MJ, Loo CE, Sonke GS, Linn SC, Falo Zamora C, Rodenhuis S.

Breast Cancer Res Treat. 2015 Aug;153(1):145-52. doi: 10.1007/s10549-015-3510-4. Epub 2015 Jul 26.

PMID:
26210520
10.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Rigter LS, Loo CE, Linn SC, Sonke GS, van Werkhoven E, Lips EH, Warnars HA, Doll PK, Bruining A, Mandjes IA, Vrancken Peeters MJ, Wesseling J, Gilhuijs KG, Rodenhuis S.

Br J Cancer. 2013 Dec 10;109(12):2965-72. doi: 10.1038/bjc.2013.661. Epub 2013 Oct 22.

11.

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J.

Breast Cancer Res Treat. 2013 Jul;140(1):63-71. doi: 10.1007/s10549-013-2620-0. Epub 2013 Jul 5.

12.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Sonke GS, Mandjes IA, Holtkamp MJ, Schot M, van Werkhoven E, Wesseling J, Vrancken Peeters MJ, Rodenhuis S, Linn SC.

Breast J. 2013 Jul-Aug;19(4):419-26. doi: 10.1111/tbj.12124. Epub 2013 May 20.

PMID:
23682812
13.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
14.

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IA, van den Bosch J, Smit WM, de Graaf H, Schröder CP, Vermeulen GJ, Hop WC, Nortier JW.

Neth J Med. 2010 Sep;68(9):371-6.

15.

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

Rodenhuis S, Mandjes IA, Wesseling J, van de Vijver MJ, Peeters MJ, Sonke GS, Linn SC.

Ann Oncol. 2010 Mar;21(3):481-7. doi: 10.1093/annonc/mdp348. Epub 2009 Aug 28.

16.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH.

Anticancer Drugs. 2001 Apr;12(4):315-23.

PMID:
11335787
17.

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, ten Bokkel Huinink WW.

Br J Cancer. 1999 Mar;79(7-8):1158-61.

18.

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Herben VM, ten Bokkel Huinink WW, Dubbelman AC, Mandjes IA, Groot Y, van Gortel-van Zomeren DM, Beijnen JH.

Br J Cancer. 1997;76(11):1500-8.

19.

High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.

Vermorken JB, ten Bokkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijnen JH, Bierhorst F, Winograd B, Pinedo HM.

Semin Oncol. 1995 Aug;22(4 Suppl 8):16-22.

PMID:
7543699
20.

Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting.

Franklin HR, Simonetti GP, Dubbelman AC, ten Bokkel Huinink WW, Taal BG, Wigbout G, Mandjes IA, Dalesio OB, Aaronson NK.

Ann Oncol. 1994 Feb;5(2):113-7.

PMID:
8186153

Supplemental Content

Loading ...
Support Center